ROIV Healthcare

Roivant Sciences Ltd.

$36.04+0.42%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United Kingdom
Market cap: 26.0B USD
Enterprise value: 22.9B USD
Full-time employees: 721

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.12 vs a peer median of 0.63)bigger price swings (beta 1.12 vs peers 0.63)

Ranks #1,009 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Operating margin at a 6-year low. -6236% in FY Mar 2026, the weakest of the last 6 years.
Roivant Sciences's operating margin fell to -6236% in FY Mar 2026, its lowest in the 6 years of filings we have.
Stock-based pay is a large cost. Stock pay was 4191% of revenue in FY Mar 2026.
Roivant Sciences paid employees $346M in stock in FY Mar 2026, 4191% of its $8M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Investment surge. Capital spending 99% of revenue, up from 40% in FY Mar 2023.
Roivant Sciences is spending 99% of revenue on facilities and equipment, up from 40% in FY Mar 2023. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Roivant Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

28/ 100

Oct 5 28 → Nov 4 28

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-1.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-5.9%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield16.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

5/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 8.8%

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-46.4%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-67.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

6/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-7914.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-5.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.24Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-15.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.04Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-6.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.12

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.47Sector median: 0.6250 · MAD: 0.3380

Current ratio16.72×

SEC filings · latest balance sheetReported value33% base weight · Z-score 10.21Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.98Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Roivant Sciences

Is Roivant Sciences getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 8.8%. Its overall score is unchanged at 28/100 since Oct 28, 2026.
How is Roivant Sciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.0% vs peers 1.5% (weaker than 100% of peers).
Is Roivant Sciences growing?: More slowly than most of its peers. Growth scores 5/100 against 1,393 healthcare peers. 3-year revenue growth -46.4% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -46.4% vs peers 5.8% (weaker than 100% of peers).
How profitable is Roivant Sciences?: Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Operating margin -7914.8% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -7914.8% vs peers 7.1% (weaker than 100% of peers).
How risky is Roivant Sciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 16.72× vs a peer median of 2.59× (stronger than 94% of peers).Current ratio 16.72× vs peers 2.59× (stronger than 94% of peers). Beta 1.12 vs a peer median of 0.63 (weaker than 77% of peers).Beta 1.12 vs peers 0.63 (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 8.8%

Worth watching: Roivant Sciences is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	8.3M USD	7.5M USD	−8.8%
Net income (12 months)	−299.8M USD	−266.3M USD	−11.2%
Operating margin	-6235.7%	-7914.8%	−1679.1 pts
Free cash flow (12 months)	−758.6M USD	−821.1M USD	+8.2%
Cash	1.4B USD	1.2B USD	−12.0%
Shares outstanding	719.3M	722.3M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Mar 2022	FY Mar 2023	FY Mar 2024	FY Mar 2025	FY Mar 2026	Change
Operating margin	-2444.8%	-2875.9%	13746.9%	-3453.3%	-6235.7%	▼ >999 pts
Net margin	-1528.9%	-3200.2%	13294.2%	-592.0%	-3629.2%	▼ >999 pts
Return on assets (ROA)	-32.7%	-42.2%	60.2%	-3.2%	-5.3%	▼ 2.1 pts
Return on equity (ROE)	-51.0%	-87.2%	72.9%	-3.7%	-6.6%	▼ 3.0 pts
Free cash flow margin	-1257.4%	-2715.1%	-2343.6%	-2905.2%	-9183.5%	▼ >999 pts
Current ratio	11.64×	6.60×	25.24×	33.47×	18.37×	▼ 45%
Quick ratio	11.64×	6.59×	25.10×	—	—	—
Debt to equity	0.13×	0.32×	0.07×	—	—	—
Interest coverage	-191.97×	-32.42×	129.31×	—	—	—

ROIV price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.12 vs a peer median of 0.63)bigger price swings (beta 1.12 vs peers 0.63)

Ranks #1,009 of 1,157 healthcare companies (bottom 13%)

See how it ranks against its peers

Worth knowing

Operating margin at a 6-year low. -6236% in FY Mar 2026, the weakest of the last 6 years.

Roivant Sciences's operating margin fell to -6236% in FY Mar 2026, its lowest in the 6 years of filings we have.

Stock-based pay is a large cost. Stock pay was 4191% of revenue in FY Mar 2026.

Roivant Sciences paid employees $346M in stock in FY Mar 2026, 4191% of its $8M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Investment surge. Capital spending 99% of revenue, up from 40% in FY Mar 2023.

Roivant Sciences is spending 99% of revenue on facilities and equipment, up from 40% in FY Mar 2023. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Roivant Sciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about Roivant Sciences

Is Roivant Sciences getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 8.8%. Its overall score is unchanged at 28/100 since Oct 28, 2026.

How is Roivant Sciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -1.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -1.0% vs peers 1.5% (weaker than 100% of peers).

Is Roivant Sciences growing?

More slowly than most of its peers. Growth scores 5/100 against 1,393 healthcare peers. 3-year revenue growth -46.4% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -46.4% vs peers 5.8% (weaker than 100% of peers).

How profitable is Roivant Sciences?

Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Operating margin -7914.8% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -7914.8% vs peers 7.1% (weaker than 100% of peers).

How risky is Roivant Sciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 16.72× vs a peer median of 2.59× (stronger than 94% of peers).Current ratio 16.72× vs peers 2.59× (stronger than 94% of peers). Beta 1.12 vs a peer median of 0.63 (weaker than 77% of peers).Beta 1.12 vs peers 0.63 (weaker than 77% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

8.3M USD

7.5M USD

−8.8%

Net income (12 months)

−299.8M USD

−266.3M USD

−11.2%

Operating margin

-6235.7%

-7914.8%

−1679.1 pts

Free cash flow (12 months)

−758.6M USD

−821.1M USD

+8.2%

Cash

1.4B USD

1.2B USD

−12.0%

Shares outstanding

719.3M

722.3M

+0.4%

Key ratios

FY Mar 2022

FY Mar 2023

FY Mar 2024

FY Mar 2025

FY Mar 2026

Change

Operating margin

-2444.8%

-2875.9%

13746.9%

-3453.3%

-6235.7%

▼ >999 pts

Net margin

-1528.9%

-3200.2%

13294.2%

-592.0%

-3629.2%

▼ >999 pts

Return on assets (ROA)

-32.7%

-42.2%

60.2%

-3.2%

-5.3%

▼ 2.1 pts

Return on equity (ROE)

-51.0%

-87.2%

72.9%

-3.7%

-6.6%

▼ 3.0 pts

Free cash flow margin

-1257.4%

-2715.1%

-2343.6%

-2905.2%

-9183.5%

▼ >999 pts

Current ratio

11.64×

6.60×

25.24×

33.47×

18.37×

▼ 45%

Quick ratio

11.64×

6.59×

25.10×

—

Debt to equity

0.13×

0.32×

0.07×

—

Interest coverage

-191.97×

-32.42×

129.31×

—